All Stories

  1. European Respiratory Society guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis
  2. Pathogenesis-driven treatment of primary pulmonary alveolar proteinosis
  3. Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
  4. Kidney manifestations of sarcoidosis
  5. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival
  6. Will inhalational GM-CSF replace whole lung lavage as a treatment for autoimmune pulmonary alveolar proteinosis? Many pole positions, not yet the final winner
  7. Pulmonale Alveolarproteinose (PAP)
  8. Pulmonale alveoläre Mikrolithiasis (PAM)
  9. Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
  10. Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 Pneumonia
  11. Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
  12. Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
  13. MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis
  14. European Respiratory Society Statement on Familial Pulmonary Fibrosis
  15. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe
  16. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective
  17. COVID-19 in patients with Pulmonary Alveolar Proteinosis A European multicenter study
  18. Genetic testing in interstitial lung disease: An international survey
  19. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
  20. Targeted therapy for pulmonary alveolar proteinosis: the time is now
  21. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
  22. Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
  23. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden
  24. Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study
  25. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
  26. Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting
  27. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
  28. S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis
  29. Potential Clinical Utility of MUC5B und TOLLIP Single Nucleotide Polymorphisms (SNPs) in the Management of Patients with IPF
  30. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis
  31. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
  32. Ganzlungenlavage bei pulmonaler Alveolarproteinose – Schritt für Schritt
  33. Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
  34. Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment
  35. When the Game Changes
  36. Hypersensitivity pneumonitis
  37. The perpetual enigma of bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: is it of diagnostic value?
  38. Looking into the future of sarcoidosis: what is next for treatment?
  39. Shedding light on developmental drugs for idiopathic pulmonary fibrosis
  40. Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19
  41. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis
  42. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review
  43. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis
  44. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis
  45. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose
  46. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
  47. Genotype in MUC5B-Promoter Polymorphism and Chronic Lung Allograft Dysfunction (CLAD) in a German Cohort: Preliminary Results
  48. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose
  49. Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
  50. Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease
  51. Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study
  52. Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung
  53. Quantitative Lipidomics in Pulmonary Alveolar Proteinosis
  54. Shaping the future of an ultra-rare disease
  55. Editorial introductions
  56. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis
  57. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
  58. Correction to: The Burden of Sarcoidosis Symptoms from a Patient Perspective
  59. Pulmonary alveolar proteinosis
  60. The Burden of Sarcoidosis Symptoms from a Patient Perspective
  61. Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipients
  62. Erratum zu: Differenzialdiagnose interstitieller Lungenerkrankungen – „Interstitial pneumonia with autoimmune features“ (IPAF)
  63. Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia
  64. Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study
  65. Differenzialdiagnose interstitieller Lungenerkrankungen
  66. Die „Rheumalunge“ in der Computertomographie: radiologische Manifestationen der rheumatoiden Arthritis
  67. The Management of Patients With Idiopathic Pulmonary Fibrosis
  68. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey
  69. Patientenfragebogen zur Erfassung der Ursachen interstitieller und seltener Lungenerkrankungen – klinische Sektion der DGP
  70. Patients with IPF and lung cancer: diagnosis and management
  71. German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017
  72. Phenotypes of organ involvement in sarcoidosis
  73. Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies
  74. Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis
  75. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis
  76. Serum YKL-40 in workers at an indium-tin oxide production facility - Reply
  77. Idiopathic pleuroparenchymal fibroelastosis (PPFE) – A case study of a rare entity
  78. Therapeutic targets in idiopathic pulmonary fibrosis
  79. Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
  80. Differential diagnosis of granulomatous lung disease: clues and pitfalls
  81. Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis
  82. S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017
  83. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis
  84. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone
  85. Coagulation factor XII regulates inflammatory responses in human lungs
  86. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis
  87. Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis
  88. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
  89. Deutschsprachige Validierung des „Kingʼs Brief Interstitial Lung Disease (K-BILD)“ Lebensqualitätsfragebogens für interstitielle Lungenerkrankungen
  90. New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis
  91. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures
  92. Epidemiologie und klinisches Erscheinungsbild der Sarkoidose
  93. A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis
  94. European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity
  95. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis
  96. How to handle IPF – the new Portuguese consensus document
  97. An Important Step Forward, but Still a Way to Go
  98. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
  99. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
  100. Pulmonary alveolar proteinosis in a cat
  101. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
  102. Pulmonale Alveolarproteinose
  103. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
  104. New guideline on treatment of idiopathic pulmonary fibrosis
  105. GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders
  106. Positionspapier zur Bedeutung der forcierten Vitalkapazität für Patienten mit idiopathischer Lungenfibrose (IPF)
  107. Facts and promises on lung biomarkers in interstitial lung diseases
  108. Diagnosis of Sarcoidosis
  109. Update on therapeutic management of idiopathic pulmonary fibrosis
  110. Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosis
  111. MUC5Bpromoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis
  112. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
  113. Alveolar and intraparenchymal proteasome in sarcoidosis
  114. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?
  115. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis
  116. Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease
  117. Interstitial lung disease
  118. Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPDgene polymorphisms
  119. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases
  120. The Ambitious Goal of Validating Prognostic Biomarkers for Systemic Sclerosis-related Interstitial Lung Disease
  121. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia
  122. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
  123. Sarkoidose
  124. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
  125. Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis
  126. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels
  127. Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases
  128. Hypersensitivity Pneumonitis
  129. Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis
  130. Chronic Hypersensitivity Pneumonitis
  131. KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndrome
  132. Self-reported asthma and respiratory symptoms among Italian amateur athletes
  133. Whole-Lung Lavage: A Successful Treatment for Restoring Acinar Ventilation Distribution in Primary Acquired Pulmonary Alveolar Proteinosis
  134. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation
  135. Pulmonary alveolar proteinosis: New insights from a single-center cohort of 70 patients
  136. Therapie der Lungenfibrose
  137. Diagnostic Modalities in Sarcoidosis: BAL, EBUS, and PET
  138. A female soccer player with recurrent haemoptysis and iron deficiency anaemia: idiopathic pulmonary haemosiderosis (IPH)--case report and literature review
  139. Angiogenic and Angiostatic Chemokines in Idiopathic Pulmonary Fibrosis and Granulomatous Lung Disease
  140. To BAL or Not to BAL: Is This a Problem in Diagnosing IPF?
  141. Die bronchoalveoläre Lavage aus klinischer Sicht
  142. Significance of Bronchoalveolar Lavage for the Diagnosis of Idiopathic Pulmonary Fibrosis
  143. Acid reflux into the oesophagus does not influence exercise-induced airway narrowing in bronchial asthma
  144. Bronchoalveolar Lavage in Other Interstitial Lung Diseases
  145. Omeprazole reduces the response to capsaicin but not to methacholine in asthmatic patients with proximal reflux
  146. Biomarkers